Mepolizumab Reduces COPD Flares in Eosinophilic Patients
-
By
May 30, 2025
-
3 min
A phase III trial revealed that mepolizumab, a monoclonal antibody targeting interleukin-5, reduced exacerbation frequency in patients with chronic obstructive pulmonary disease (COPD) and elevated eosinophil levels. The study enrolled 804 participants and demonstrated a 21% relative reduction in exacerbation rate with mepolizumab compared to placebo, along with longer time to first exacerbation and fewer emergency visits or hospitalizations.
1. Mepolizumab, targeting IL-5, reduced COPD exacerbation frequency and emergency visits/hospitalizations. 2. Study included 804 COPD patients with elevated eosinophil levels. 3. Participants receiving mepolizumab showed a 21% relative reduction in exacerbation rate. 4. Time to first exacerbation was longer with mepolizumab. 5. No significant differences in patient-reported outcomes were observed. 6. Adverse events were reported in 74% of the mepolizumab group and 77% of the placebo group. 7. Common adverse events with mepolizumab included worsening COPD and SARS-CoV-2 infection.
Listen Tab content
